In the last trading session, 2.22 million Bone Biologics Corp (NASDAQ:BBLG) shares changed hands as the company’s beta touched 0. With the company’s per share price at $0.61 changed hands at -$0.17 or -21.79% during last session, the market valuation stood at $1.91M. BBLG’s last price was a discount, traded about -2063.93% off its 52-week high of $13.20. The share price had its 52-week low at $0.47, which suggests the last value was 22.95% up since then. When we look at Bone Biologics Corp’s average trading volume, we note the 10-day average is 5.19 million shares, with the 3-month average coming to 1.01 million.
Analysts gave the Bone Biologics Corp (BBLG) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BBLG as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Bone Biologics Corp’s EPS for the current quarter is expected to be -$0.61.
Bone Biologics Corp (NASDAQ:BBLG) trade information
Instantly BBLG was in red as seen at the end of in last trading. With action 20.10%, the performance over the past five days has been green. The drop to weekly highs of 0.9980 on Friday, 11/17/23 subtracted -21.79% to the stock’s daily price. The company’s shares are showing year-to-date downside of -90.30%, with the 5-day performance at 20.10% in the green. However, in the 30-day time frame, Bone Biologics Corp (NASDAQ:BBLG) is -0.81% down. Looking at the short shares, we see there were 9330.0 shares sold at short interest cover period of 0.16 days.
The consensus price target for the stock as assigned by Wall Street analysts is $7.50, meaning bulls need an upside of 91.87% from its current market value. According to analyst projections, BBLG’s forecast low is $7.50 with $7.50 as the target high. To hit the forecast high, the stock’s price needs a -1129.51% plunge from its current level, while the stock would need to soar -1129.51% for it to hit the projected low.
Bone Biologics Corp (BBLG) estimates and forecasts
Data shows that the Bone Biologics Corp share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -86.36% over the past 6 months, a 17.18% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Bone Biologics Corp will rise 83.10%, while the growth in revenue is estimated to hit 87.00% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 50.78%. The 2023 estimates are for Bone Biologics Corp earnings to decrease by -60.30%.
Bone Biologics Corp is expected to release its next quarterly earnings report on November 14.
Bone Biologics Corp (NASDAQ:BBLG)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.61% of Bone Biologics Corp shares while 3.23% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 3.74%. There are 3.23% institutions holding the Bone Biologics Corp stock share, with Walleye Capital LLC the top institutional holder. As of Jun 29, 2023, the company held 9.41% of the shares, roughly 0.29 million BBLG shares worth $0.42 million.
Kepos Capital Lp holds the second largest percentage of outstanding shares, with 1.60% or 50000.0 shares worth $71500.0 as of Jun 29, 2023.
With 197.0 shares estimated at $1001.0 under it, the former controlled 0.01% of total outstanding shares.